ACHA
Meeting category
Date(s)
9 May 2014 - 10 May 2014
Location
Beijing, China
Organizer

Asian Conference on Hepatitis and AIDS (ACHA) 2014

Related Enduring Materials

Enduring Materials

Friday, 9 May 2014

-
Opening Words
George Gao, DVM, DPhil
Beijing Institutes of Life Science, CAS & CDC, China
HBV Mini-symposium -
What should we do to cure HBV
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Some thoughts on strategies for reverting immune tolerance versus HBV infections
placeholder3
Yumei Wen, MD
Shanghai Medical school Fudan University, China
Cure for HBV - Correlates & Differences
Sharon Lewin, AO, FRACP, PhD, FAHMS
Peter Doherty Institute for Infection and Immunity, Australia
Antiviral therapy of HBV/HCV in China from clinical perspective
Jidong Jia, MD, PhD
Beijing Friendship Hospital, China
Session 1: HIV -
HIV Cure
Sharon Lewin, AO, FRACP, PhD, FAHMS
Peter Doherty Institute for Infection and Immunity, Australia
HIV co-infections from a European Perspective
Jürgen Rockstroh, MD
University of Bonn, Germany
HIV Clinical Implications
Taisheng Li, MD, PhD
Peking Union Medical College Hospital, China
Rationale for starting therapy early
Charles Boucher, MD, PhD
Erasmus Medical Center, The Netherlands
Update on HIV drug resistance
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
Treatment strategies in special populations (women, aging patients, late presenters)
Jürgen Rockstroh, MD
University of Bonn, Germany
Case Discussions
Bonaventura Clotet, MD, PhD
Universitat Autònoma de Barcelona, Spain
Satellite Symposium

Saturday, 10 May 2014

Session 2: HBV -
Has treating HBV reduced liver cancer incidence?
Jinlin Hou, MD
Nanfang Hospital, Southern Medical University, China
How does HBV cause cancer?
Fengmin Lu, MD, PhD
Peking University, China
HBV Entry and Receptor General Discussion
Wenhui Li
Wenhui Li, PhD
National Institute of Biological Science, China
Can chronic hepatitis B be cured? Evidence from clinical and basic studies
Fusheng Wang
Fusheng Wang, MD, PhD
Beijing 302 Hospital of PLA, China
Session 3: HCV -
Innate immune responses to HCV Infection
Kui Li
Kui Li, MD
University of Tennessee Health Science Center, USA
Hepatitis C disease burden from Asian perspective
Hui Zhuang, MD
Peking University Health Science Center, China
Abbvie Lunch Symposium
DAA’s Role in the USA
placeholder3
Donald Jensen, MD
RUSH University Medical Center, USA
DAA’s Role in Asia
Lai Wei, MD, PhD
Beijing Tsinghua Changgung Hospital, China
IL-28B genotype, to detect or not to detect
Huiying Rao
Huiying Rao, MD, PhD
The People’s Hospital Beijing University, China
Clinical management of hepatitis C patients: to treat or to wait
Ed Gane
Ed Gane, MBChB, MD, FRACP, MNZM
Auckland City Hospital, New Zealand
Managing HCV in HIV infected patients
Weiping Cai, MD, PhD
Guangzhou Medical University, China
Managing HCV in cirrhotic patients
placeholder3
Qing Xie, MD, PhD
Rujin Hospital Shanghai Jiaotong University
Closing remark
Overview
Welcome

The 3rd Asian Conference on Hepatitis and AIDS - From Basic Science to Clinical Practice, was held in Beijing, China on 9 - 10 May 2014 at the Beijing University.  

The Organizing Committee would like to thank all invited speakers and participants for their contribution to this conference!

We would like to thank our sponsor AbbVie (Platinum), Gilead (Supporter), the Chinese Society of Hepatology, CMA and the Chinese AIDS Society (Endorsers) for making this event possible.

The Executive Committee

General Information 

Unique Features
- A program with a special focus on the needs in China and Asia

- A true scientific platform for local and regional clinicians and clinical researchers to present their data

- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
Meeting Objectives
This meeting aims to:

- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections

- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice

- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
Learning Objectives
After participating in this activity, participants will be able to:

- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV

- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals

Practical Information 

Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Support
Endorsers
Language